Why the study?
Traditional HCM therapies offer symptomatic relief without targeting underlying molecular pathology, and the role of cardiac myosin inhibitors in non-obstructive disease remains uncertain.
Design
Review
Key result
Cardiac myosin inhibitors have transformed the management of obstructive hypertrophic cardiomyopathy, while their role in non-obstructive disease remains uncertain.
Authors
Loading...
May support targeted HCM therapies in select patients; leaves open need for confirmatory RCTs before practice change.
This review highlights the transformative impact of cardiac myosin inhibitors on obstructive hypertrophic cardiomyopathy and outlines emerging targeted therapies for broader disease modification.
Smoot et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Cardiac myosin inhibitors (CMIs) was evaluated. Cardiac myosin inhibitors have transformed the management of obstructive hypertrophic cardiomyopathy, while their role in non-obstructive disease remains uncertain.